Discussion topic: |
The power and limitations of immunobridging studies: the example of COVID-19 vaccines |
Presentations : Bridging studies – why and how? Criteria and requirement for the licensing of new vaccines with special emphasis on COVID-19 Finnish Institute for Health and Welfare, Finland and Member of the ADVAC Scientific Committee |
The power and limitations of immunobridging studies: the example of COVID-19 vaccines
- Details